US2014037773A1PendingUtilityA1

Composition for improving inflammatory disease using abh antigens

36
Assignee: OH JANG HEEPriority: Jan 9, 2009Filed: Aug 30, 2013Published: Feb 6, 2014
Est. expiryJan 9, 2029(~2.5 yrs left)· nominal 20-yr term from priority
Inventors:Jang Hee OhJi Yong JungDong Hun LeeSerah LeeYeon Kyung KimJeong Eun ShinJune H. LeeJin Ho Chung
A61P 37/00A61P 29/00A61P 27/02A61P 17/00A61P 17/10A61P 13/00A61P 1/04A61P 17/06A61K 36/76A61K 9/2059A61K 47/26A61K 36/28A61K 9/0019C12N 2310/14A61K 8/60A61K 8/9789A61K 36/254A61Q 19/08A61K 36/258A61K 39/0005A61K 8/06A61K 9/107C12Y 204/01041A61K 9/0014C12N 15/1137A61K 9/08A61K 9/0095A61K 36/539A61K 36/07A61K 31/7105A61K 39/395A61K 9/06A61K 8/97
36
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides a method for treating an inflammatory skin disease in a subject comprising administering to the subject an amount of composition comprising willow tree extract as an active ingredient effective to treat the inflammatory skin disease.

Claims

exact text as granted — not AI-modified
1 - 14 . (canceled) 
     
     
         15 . A method for treating an inflammatory skin disease in a subject comprising administering to the subject an amount of a composition comprising willow tree extract as an active ingredient effective to treat the inflammatory skin disease. 
     
     
         16 . The method according to  claim 15 , wherein the inflammatory skin disease is selected from the group consisting of psoriasis, atopic dermatitis, ichthyosis, pemphigus, acne, lupus erythematosus, skin aging and wrinkles. 
     
     
         17 . The method according to  claim 15 , wherein the willow tree extract is included in the composition at the concentration of 0.001-10 weight % by the total weight of the composition. 
     
     
         18 . The method according to claim  1 , wherein the composition is prepared in the form of a pharmaceutical composition or a cosmetic composition. 
     
     
         19 . The method according to  claim 18 , wherein the composition is formulated as an external preparation for skin. 
     
     
         20 . The method according to  claim 18 , wherein the cosmetic composition is selected from the group consisting of skin, nourishing skin, massage cream, nourishing cream, pack, gel, adhesive-type cosmetic preparation, lotion, ointment, gel, cream, patch and spray. 
     
     
         21 . The method according to  claim 18 , wherein the pharmaceutical composition is in a form for oral or parenteral administration selected from the group consisting of solid formulation, semi-solid formulation, and liquid formulation. 
     
     
         22 . A method for increasing the expression of ABH antigen in a subject comprising administering to the subject an amount of a composition comprising willow tree extract as an active ingredient effective to increase the expression of ABH antigen. 
     
     
         23 . The method according to  claim 22 , wherein the willow tree extract is included in the composition at the concentration of 0.001-10 weight % by the total weight of the composition. 
     
     
         24 . The method according to  claim 22 , wherein the composition is prepared in the form of a pharmaceutical composition or a cosmetic composition. 
     
     
         25 . The method according to  claim 24 , wherein the composition is formulated as an external preparation for skin. 
     
     
         26 . The method according to  claim 24 , wherein the cosmetic composition is selected from the group consisting of skin, nourishing skin, massage cream, nourishing cream, pack, gel, adhesive type cosmetic preparations, lotion, ointment, gel, cream, patch and spray. 
     
     
         27 . The method according to  claim 24 , wherein the pharmaceutical composition is in a form for oral or parenteral administration selected from the group consisting of solid formulation, semi-solid formulation, and liquid formulation. 
     
     
         28 . The method according to  claim 22 , wherein the ABH antigen is selected from the group consisting of type A antigen wherein N-acetylgalactosamine is conjugated on fucose-galactose terminal, type B antigen wherein galactose is conjugated on fucose-galactose terminal, type AB antigen wherein both N-acetylgalactosamine and galactose are conjugated on fucose-galactose terminal and type H antigen wherein both N-acetylgalactosamine and galactose are not conjugated on fucose-galactose terminal. 
     
     
         29 . The method according to  claim 22 , wherein the ABH antigen is selected from the group consisting of fucose, galactose, glucose, N-acetylgalactosamine, N-acetylglucosamine, FG (Fucose:Galactose=1:1, H-antigen composition), FGG (Fucose:Galactose=1:2, B-antigen composition) and FGGN (Fucose:Galactose:N-acetylgalactosamine=1:1:1, A-antigen composition).

Join the waitlist — get patent alerts

Track US2014037773A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.